跳至主要内容
临床试验/CTRI/2022/10/046550
CTRI/2022/10/046550暂停1/2 期

A Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Ashwagandha (Withania somnifera)Extract in the management of Insomnia

Arjuna Natural Private Limited,1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2022年10月19日最近更新:

试验速览

阶段
1/2 期
状态
暂停
入组人数
50
试验地点
1
主要终点
Mean change in Sleep questionnaires

研究概览

简要总结

This is a randomized, double-blind, placebo-controlled study in participants with disturbed sleep.  Qualified participants will be randomized into two groups in 1:1 ratio to test product or placebo and advised to take 500 mg of capsule for 30 days. The participants were assessed by sleep questionnaires and sleep diary.

研究设计

研究类型
Interventional
分配方式
Computer generated randomization
盲法
Participant, Investigator and Outcome Assessor Blinded

入排标准

年龄范围
25.00 Year(s) 至 64.00 Year(s)(—)
性别
All

入选标准

  • A primary complaint of sleep-onset insomnia for at least 6 months defined as a sleep-onset latency of at least 1 hour over 3 nights a week as verified by pre-screening sleep diaries
  • At least 1 negative daytime complaint (eg, fatigue, impaired mood, or performance) attributed to insomnia
  • Pittsburgh Sleep Quality Index (PSQI) Score > 5
  • Insomnia Severity Index (ISI) Score 15 – 21
  • Athens Insomnia scale score >10
  • STOP-BANG score < 3
  • Sleep Onset Latency >31 minutes a night, as confirmed by the pre-screening sleep diary 8.

排除标准

  • Current use of prescription or over-the-counter sleep medications or unwillingness or inability to discontinue use of these medications at least 4 weeks before beginning the study
  • Medical problems that would be a direct cause of insomnia
  • Current treatment for depression, alcohol or substance abuse, or psychosis
  • Previous diagnosis of sleep apnea or periodic limb movements or prior CBT for insomnia
  • Initiation of psychotherapy in the previous 6 months
  • Women of childbearing age who were pregnant, breastfeeding, or not practicing contraception
  • Shift work
  • Epworth Sleepiness Scale (ESS) a score ≥ 9
  • Beck depression inventory-II(BDI-II) > 13
  • Any condition, including laboratory abnormalities, that in the opinion of investigator places the volunteer at an unacceptable risk or deems the volunteer not suitable for participation in the study.

结局指标

主要结局

Mean change in Sleep questionnaires

时间窗: Baseline, Day 15 and Day 30

次要结局

  • Assessment of Sleep diary(Baseline to Day 30)

研究者

申办方类型
Other [Neutraceutical company]

研究点 (1)

Loading locations...

相似试验